Description: Telomir Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, is engaged in the advancement of age reversal science. The company is developing Telomir 1, a small molecule intended to lengthen and protect telomeres, the DNA end caps of chromosomes that are associated with cellular aging. Telomir 1 is designed for oral administration and is aimed at extending longevity, improving quality of life, and potentially influencing biological aging. Telomir Pharmaceuticals is also involved in ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and other age related conditions to assess the potential effects of Telomir 1. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Home Page: telomirpharma.com
100 SE 2nd St.
Miami,
FL
33131
United States
Phone:
813-864-2558
Officers
| Name | Title |
|---|---|
| Mr. Erez Aminov | Chairman of the Board & CEO |
| Dr. Francis E. O'Donnell Jr., M.D. | Co-founder, Chief Medical Officer & Special Advisor |
| Ms. Michelle Yanez M.B.A. | Chief Financial Officer |
| Dr. Itzchak Angel Ph.D. | Chief Scientific Advisor |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 340.9247 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-02-09 |
| Fiscal Year End: | September |
| Full Time Employees: | 1 |